Fexofenadine

Oral
Seasonal allergic rhinitis

Oral
Chronic idiopathic urticaria

Should be taken on an empty stomach. Do not take w/ fruit juice.

Patient with current or history of CV disease. Renal and hepatic impairment. Children. Pregnancy and lactation.

Cardiac disorders: Palpitations, tachycardia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, dyspepsia.
General disorders and administration site conditions: Fatigue.
Immune system disorders: Hypersensitivity reactions (e.g. angioedema, chest tightness, flushing).
Nervous system disorders: Headache, drowsiness, dizziness.
Psychiatric disorders: Insomnia, nervousness, sleep disorders or nightmares.
Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.

Monitor relief of symptoms.

Symptoms: Dizziness, drowsiness, fatigue and dry mouth. Management: Symptomatic and supportive treatment.

Increased plasma concentrations with erythromycin and ketoconazole. Reduced bioavailability and absorption with antacids containing Al and Mg.

Decreased bioavailability with high-fat meals, fruit juice (e.g. apple, grapefruit, orange).

May suppress the wheal and flare reactions to skin test antigens.

Description:
Mechanism of Action: Fexofenadine is a non-sedating antihistamine and an active metabolite of terfenadine. It competes with histamine for H₁-receptor on effector cells in the blood vessels, gastrointestinal tract and respiratory tract.
Onset: 2 hours.
Duration: 24 hours.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: Approx 33%; decreased with high-fat meals, fruit juice. Time to peak plasma concentration: Approx 2.6 hours (conventional tab); 2 hours (orally disintegrating tab); approx 1 hour (susp).
Distribution: Plasma protein binding: 60-70%, mainly to albumin and α₁-acid glycoprotein.
Metabolism: Undergoes minimal metabolism in the liver (approx 5%) into methylester metabolite.
Excretion: Mainly via faeces (80%); urine (12%, as unchanged drug). Elimination half-life: 14.4 hours.

Source: National Center for Biotechnology Information. PubChem Database. Fexofenadine, CID=3348, https://pubchem.ncbi.nlm.nih.gov/compound/Fexofenadine (accessed on Jan. 20, 2020)

Store between 20-25°C.

Thuốc kháng histamin & kháng dị ứng

R06AX26 - fexofenadine ; Belongs to the class of other antihistamines for systemic use.

Anon. Fexofenadine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/03/2022.

Buckingham R (ed). Fexofenadine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2022.

Childrens Fexofenadine Hydrochloride Allergy Suspension (Taro Pharmaceuticals U.S.A., Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/02/2022.

Fexofenadine Cipla 120 mg Film-Coated Tablets (Cipla [EU] Limited). MHRA. https://products.mhra.gov.uk. Accessed 10/02/2022.

Fexofenadine HCL Tablet (Akron Pharma Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/02/2022.

Fexofenadine Hydrochloride 180 mg Film-Coated Tablets (Generics [UK] Limited t/a Mylan). MHRA. https://products.mhra.gov.uk. Accessed 10/02/2022.

Joint Formulary Committee. Fexofenadine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2022.

Pharmacy Retailing (NZ) Limited Trading as Healthcare Logistics. Telfast 6-11 Years 30 mg Film Coated Tablets; Telfast 60 mg Film Coated Tablets; Telfast 120 mg Film Coated Tablets; Telfast 180 mg Film Coated Tablets; Telfast Oral Liquid, 6 mg/mL Suspension data sheet 20 December 2021. Medsafe. http://www.medsafe.govt.nz. Accessed 10/02/2022.

Telfast 180 mg Tablets (DKSH Malaysia Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/02/2022.

Telfast 30 mg Film-Coated Tablets (Sanofi). MHRA. https://products.mhra.gov.uk. Accessed 10/02/2022.

Telfast 30 mg/5 mL Oral Suspension (DKSH Malaysia Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/02/2022.